solomon

I follow you down

[RedChip @RedChip]

Calidi Biotherapeutics $CLDI: RedTail Systemic Virotherapy Platform Advances Toward IND Submission as CEO Eric Poma Outlines the Investment Case

$CLDI CEO Eric Poma, PhD explains how Calidi's proprietary RedTail platform addresses one of oncology's most persistent challenges: delivering oncolytic virotherapy systemically to metastatic tumors without immune clearance eliminating the therapy before it reaches its target.

Watch the full interview: https://t.co/XILoqV1Bcg

$CLDI $PFE $AMGN $JNJ $CADL $BMRN $CPRX $CGON $REPL $NBTX $IBRX

[solomon @SolomonC85]

@market_sleuth Better reporting than anything you would ever see on TV.

[Calidi Biotherapeutics @CalidiBio]

$CLDI's CEO, Eric Poma, discusses the potential of systemically delivered oncolytic viruses for metastatic cancer and Calidi's approach to targeted payload delivery in a new @Xtalks interview.

Full article: https://t.co/olyV1QJkNe

[RedChip @RedChip]

Top scientists and Pfizer’s former CMO are backing Calidi Biotherapeutics (New York Stock Exchange American: $CLDI).

Why? Because its systemic genetic delivery platform could redefine how we treat cancer.

🎥 Watch our 30-sec investor overview.
🔗 https://t.co/NYi1wHkhLW

$CLDI $PFE $AMGN $JNJ $CADL $BMRN $CPRX $CGON $REPL $NBTX $IBRX

[Calidi Biotherapeutics @CalidiBio]

.Hear from $CLDI's CEO Eric Poma, Ph.D., as he discusses the Company's innovative approach to targeted genetic medicines via its proprietary RedTail platform and recent progress for lead candidate CLD-401 in an interview with @RedChip.

[Calidi Biotherapeutics @CalidiBio]

$CLDI presented data today on its approach of simultaneously activating T-cells while inducing the expression of T-cell engagers specifically in situ in the tumor microenvironment at the T-cell Engager Therapeutic Summit.

Read more here: https://t.co/YNqiukMLFV

@HansonWade

[Calidi Biotherapeutics @CalidiBio]

$CLDI has appointed Corsee Sanders, Ph.D., to its Board of Directors.

Dr. Sanders brings 30+ years of biopharmaceutical development experience, including leadership roles at Genentech, Roche, and Bristol Myers Squibb.

Read more: https://t.co/fqB98wZyzm

[RedChip @RedChip]

Top scientists and Pfizer’s former CMO are backing Calidi Biotherapeutics (New York Stock Exchange American: $CLDI).

Why? Because its systemic genetic delivery platform could redefine how we treat cancer.

🎥 Watch our 30-sec investor overview.
🔗 https://t.co/NYi1wHkhLW

$CLDI $PFE $AMGN $JNJ $CADL $BMRN $CPRX $CGON $REPL $NBTX $IBRX

[Calidi Biotherapeutics @CalidiBio]

The $CLDI team is looking forward to an exciting week at the #BIO2026! Please reach out to our team if you’re interested in connecting.

[RedChip @RedChip]

Calidi Biotherapeutics $CLDI: RedTail Systemic Virotherapy Platform Advances Toward IND Submission as CEO Eric Poma Outlines the Investment Case

$CLDI CEO Eric Poma, PhD explains how Calidi's proprietary RedTail platform addresses one of oncology's most persistent challenges: delivering oncolytic virotherapy systemically to metastatic tumors without immune clearance eliminating the therapy before it reaches its target.

Watch the full interview: https://t.co/XILoqV1Bcg

$CLDI $PFE $AMGN $JNJ $CADL $BMRN $CPRX $CGON $REPL $NBTX $IBRX

[Calidi Biotherapeutics @CalidiBio]

$CLDI is advancing CLD-401 toward first-in-human studies following FDA regulatory feedback on the program's development strategy.

Read more: https://t.co/hhOOjruuNM

[Calidi Biotherapeutics @CalidiBio]

In a new guest column with Drug Delivery Leader, $CLDI's CEO Eric Poma explores the potential of oncolytic virotherapy to selectively target tumors and enhance therapeutic activity within the tumor microenvironment.

Read the full column: https://t.co/neVOJKErpG

#Oncology

[RedChip @RedChip]

Top scientists and Pfizer’s former CMO are backing Calidi Biotherapeutics (New York Stock Exchange American: $CLDI).

Why? Because its systemic genetic delivery platform could redefine how we treat cancer.

🎥 Watch our 30-sec investor overview.
🔗 https://t.co/NYi1wHkhLW

$CLDI $PFE $AMGN $JNJ $CADL $BMRN $CPRX $CGON $REPL $NBTX $IBRX

[Calidi Biotherapeutics @CalidiBio]

$CLDI's CEO Eric Poma joined the @NanoCapPod to discuss Calidi's oncolytic virus platform, its potential to transform cancer treatment, and the Company's clinical strategy.

Listen:
@Spotify: https://t.co/eVX5gXc2yX
@ApplePodcasts: https://t.co/TjX1IGBt0p

[Calidi Biotherapeutics @CalidiBio]

$CLDI's CEO, Dr. Eric Poma, will participate in an investor webinar hosted by @RedChip on June 9, at 1:15pm PT. Dr. Poma will share an in-depth overview of Calidi's breakthrough RedTail platform & highlight the progress of its lead candidate, CLD-401.

🔗 https://t.co/xCakwm1qMb

[RedChip @RedChip]

Calidi Biotherapeutics (NYSE-A: $CLDI): CEO to Discuss CLD-401 Progress and RedTail Platform in June 9 Investor Webinar

The webinar will feature CEO Eric Poma, Ph.D., who is expected to provide an update on the company's RedTail platform and the advancement of CLD-401 toward a planned IND submission by the end of 2026.

The discussion will cover recent preclinical data demonstrating tumor-selective viral replication, immune evasion capabilities, and localized expression of an IL-15 superagonist payload, along with upcoming development milestones and broader platform opportunities.

Register now: https://t.co/2A3PxASxCv

$CLDI $PFE $AMGN $JNJ $CADL $BMRN $CPRX $CGON $REPL $NBTX $IBRX

[RedChip @RedChip]

Top scientists and Pfizer’s former CMO are backing Calidi Biotherapeutics (New York Stock Exchange American: $CLDI).

Why? Because its systemic genetic delivery platform could redefine how we treat cancer.

🎥 Watch our 30-sec investor overview.
🔗 https://t.co/NYi1wHkhLW

$CLDI $PFE $AMGN $JNJ $CADL $BMRN $CPRX $CGON $REPL $NBTX $IBRX

[solomon @SolomonC85]

@ThierryBorgeat Yep that was in Barron's last week

[solomon @SolomonC85]

@contractorkeith Could be a lot of things

[solomon @SolomonC85]

@NormOrnstein Yes